Antiphospholipid Antibodies and Fetal Growth Restriction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Antiphospholipid Syndrome is an immune disease where the presence of antibodies directed against cell membrane phospholipids (antiphospholipid antibodies) can cause an hypercoagulable state that causes thrombosis and obstetric complications (miscarriages, stillbirths). Since 1999 the Sapporo Criteria for Antiphospholipid Syndrome diagnosis includes the development of fetal growth restriction (diagnosed postpartum), but this was done without solid evidence of a relation between the two or using the most common form of fetal growth restriction diagnosis (ultrasound). Our study will try to add information to this particular point.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antiphospholipid Antibodies and Early Severe Preeclampsia.

NCT01538121

Severe Preeclampsia Antiphospholipid Syndrome

UNKNOWN

Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.

NCT00180817

Antiphospholipid Syndrome

COMPLETED

The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations

NCT02855047

Antiphospholipid Syndrome

COMPLETED

Perinatal Outcome After Premature Rupture of Membranes

NCT01538030

Fetal Membranes Premature Rupture

COMPLETED

Neutrophil Extracellular Traps Mediate Antiphospholipid Antibody-induced Pregnancy Loss

NCT03735108

Neutrophil Extracellular Traps; Antiphospholipid Antibody-induced Pregnancy Loss

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fetal Growth Restriction Antiphospholipid Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cases

Patients with ultrasonographic diagnosis of fetal growth restriction.

No interventions assigned to this group

Control

Patients with normal pregnancies at term.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Gestational age between 24-34 weeks.
* Ultrasonographic evidence of fetal growth restriction

* Abdominal circumference \< 3rd percentile.
* Doppler with increase of placental resistance.